1-855-378-42281-855-378-4228
One of the out-patient treatment options for people in Bellewood struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed facilities and doctors are certified to give certain medications to opioid dependent clients, many of which are opioid-based themselves and are habit forming. In low enough amounts however, the individual does not experience being high and also doesn't have severe cravings and isn't experiencing opioid withdrawal. Methadone is the first med used for this purpose, but there are a few more options to select from.
Methadone is an opiate and is meant to be taken at an outpatient medical center licensed to administer the med, which is taken daily as a pill or liquid. The price of the drug is about one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based med, and is in pill form often taken one day on, one day off. But unlike Methadone that can only be administered in highly well-regulated clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The monthly cost of buprenorphine is about $300 per month for the generic version of the medication. There is also a version of buprenorphine that contains the ingredient naloxone, which is a med that blocks the effects of opioids. An individual consuming this version of the drug, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken every day, and costs approximately $450 /month. Naltrexone is an additional med taken in opioid maintenance therapy, but unlike the other drugs aforementioned it is an opiate blocker and is not an opiate. There is an option to take this drug as a monthly shot, and that is called Vivitrol. As an opioid blocker, it prevents a person from feeling high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 per month.
For All Alcohol and Drug Rehabilitation Programs In Bellewood, Click Here.
